New drug duo aims to outsmart melanoma that resists standard treatment

NCT ID NCT05130177

Ongoing Disease control Sponsor: Diwakar Davar Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, in 8 adults with melanoma that stopped responding to PD-1 inhibitors. The goal is to see if the combination can shrink tumors or stop them from growing. The study is active but no longer recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zimberelimab and Domvanalimab (two immunotherapy drugs that help the immune system attack cancer)
What this could lead to: If successful, this combination could offer a new treatment option for people with melanoma that no longer responds to standard immunotherapy.
What could go wrong: This is a very small early-phase trial with only 8 participants, so results may not apply to everyone. The drugs can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.